Safety and tolerability of of standard antiviral therapy (peginterferon + ribavirin) in combination with deferasirox in patients with chronic hepatitis C and chronic transfusion-dependent anemias.

Trial Profile

Safety and tolerability of of standard antiviral therapy (peginterferon + ribavirin) in combination with deferasirox in patients with chronic hepatitis C and chronic transfusion-dependent anemias.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2015

At a glance

  • Drugs Deferasirox (Primary) ; Peginterferon; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top